HLS Therapeutics Inc.
HLTRF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -4.7% | 12.3% | -18.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 81.2% | 82.3% | 81% | 82.7% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 29.8% | 33.3% | 23.1% | 30.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -29% | -19.3% | -35.1% | -19.5% |
| EPS Diluted | -0.12 | -0.088 | -0.14 | -0.095 |
| % Growth | -36.2% | 37.1% | -47.5% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |